Time-driven activity-based costing (TDABC) is suggested to assess costs within the value-based healthcare approach, but there is a paucity of applications in chronic diseases such as deep vein thrombosis (DVT) and leg ulcers. In this context, we applied TDABC in a cost-effectiveness analysis comparing venous stenting to compression ± anticoagulation (standard of care—SOC) from both hospital and societal perspectives in Italy. TDABC was applied to both treatments to assess costs that were included in a cost-effectiveness model. Clinical inputs were retrieved from the literature and integrated with real-world data. The Incremental Cost Utility Ratio (ICUR) of stenting compared to SOC was EUR 10,270/QALY and EUR 8962/QALY for hospital and societal perspectives, respectively. The mean cost per patient for venous stenting of EUR 5082 was higher than the Diagnosis-Related Group (DRG) reimbursement (EUR 4742). For SOC, an ulcer healing in 3 months costs EUR 1892, of which EUR 302 (16%) is borne by the patient versus a reimbursement of EUR 1132. TDABC showed that venous stenting may be cost-effective compared with SOC but that reimbursement rates may not completely cover the real costs, which are partially sustained by the patients. A more efficient policy for covering the real costs may be beneficial for both clinical centers and patients.
Chronic ulcers require prolonged care and carry an increased risk of infection and limb loss. Sequencing studies of diabetic foot ulcers, venous leg ulcers, and pressure ulcers have revealed dynamic, patient-specific microbial communities whose composition varies with local tissue conditions and treatment exposure. This review examines changes in microbial burden and community structure during wound-bed and antimicrobial interventions and their relationships with healing. Observed shifts may contribute to therapeutic effects, reflect direct perturbation of the community, or follow tissue recovery. However, most studies are small, heterogeneous, and uncontrolled, limiting causal inference. No published randomized trial has shown that treatment selection informed by sequencing-based microbial profiling improves wound healing. A central translational challenge is to determine whether baseline microbial features reproducibly predict responses to defined interventions. Progress will therefore require prospective longitudinal studies integrating sequencing with quantitative culture, isolate phenotyping, antimicrobial susceptibility testing, biofilm assays, and standardized clinical data. Such studies should establish whether microbiome profiling adds clinically useful information to conventional wound assessment and microbiological testing.